drugset / Trial / NCT06194799
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
NaSingle-groupOpen-labelTreatment
Summary
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.
Timeline
- Start
- 2024-04-23
- Primary completion
- 2029-04
- Completion
- 2029-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACP-204 | Unknown | 30 mg | — |
| Subject | ACP-204 | Unknown | 60 mg | — |